In a move likely to boost the use of Bharat Biotech’s anti-Covid vaccine Covaxin, the drug regulator’s subject expert committee (SEC) on Wednesday recommended doing away with the “clinical trial mode” for its use and making it a case of regular emergency use authorisation., In a move likely to boost the use of Bharat Biotech’s anti-Covid vaccine Covaxin, the drug regulator’s subject expert committee (SEC) on Wednesday recommended doing away with the “clinical trial mode” for its use and making it a case of regular emergency use authorisation., , Read More
AAS Yoga
Go for Euphoria – Illness to Wellness the Natural Way